McClain. S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes. Am
nol, and acetaminophen (4, 7, 20, 35) . These hepatotoxins induce hepatic deficiencies of AdoMet and GSH. Although the mechanisms of its action are not fully established, one potential beneficial effect of AdoMet is attenuation of proinflammatory cytokine production by endotoxin (LPS)-stimulated monocytes/macrophages (6) . TNF-␣ is a pleiotropic inflammatory cytokine and an important mediator of toxin-induced liver injury (2, 9, 17) . It has recently been shown (38) that AdoMet supplementation to RAW 264.7, a murine macrophage cell line, decreases the amount of TNF-␣ released in the conditioned medium and the steady-state mRNA concentrations following LPS stimulation.
IL-10, initially named cytokine synthesis inhibitory factor, is an important suppressor of both immunoproliferative and inflammatory responses (30, 33) . Exogenous IL-10 downregulates monocyte/macrophage effector functions including production of certain proinflammatory cytokines such as TNF-␣ and IL-1␤ (27) . Inadequate monocyte production of IL-10 has been postulated to play a role in increased TNF production and subsequent liver injury in alcoholic liver disease (ALD) (18) . In addition, IL-10 may also exert antifibrotic effects in the liver through inhibition of collagen gene transcription and increased collagenase expression by hepatic stellate cells (37) . The effect(s) of AdoMet concentration (including exogenous administration of AdoMet) on IL-10 production in monocytes have not been examined. In the present study, we evaluated the effects of AdoMet both on IL-10 protein synthesis and gene expression in LPS-stimulated RAW cells.
METHODS
Materials. RAW 264.7 murine monocytes were obtained from the American Type Culture Collection (ATCC, Manassas, VA). AdoMet, as its 1,4-butanedisulphonate salt, was provided by Drs. R. O'Brian (Knoll Pharmaceuticals, Piscataway, NJ) and G. Stramentionoli (Knoll Farmaceutici, Milan, Italy). LPS (Escherichia coli O111:B4) was purchased from Difco Laboratories (Detroit, MI). Before use, LPS was dissolved in sterile, pyrogen-free water, sonicated, and diluted with sterilized HBSS. Penicillin, streptomycin, DMEM, tryp-sin, fetal bovine serum, and TRIzol reagent were purchased from Invitrogen (Grand Island, NY); 24-and 96-well plates were from Corning (Corning, NY); and murine IL-10, TNF-␣, and cAMP ELISA kits were from Biosource International (Camarillo, CA). Purified hamster anti-mouse/rat TNF antibody, RiboQuant in vitro transcription kit, RiboQuant ribonuclease protection assay (RPA) kit, and mCK-2 RiboQuant mouse cytokine multi-probe template kit were from PharMingen (San Diego, CA). SQ 22536 and H-89 were from Calbiochem (San Diego, CA). All other reagents were of the highest purity available and, unless indicated otherwise, were obtained from Sigma (St. Louis, MO).
Cell culture. RAW 264.7 cells were cultured in DMEM containing 10% (vol/vol) fetal bovine serum, 2 mM glutamine, 5 U/ml penicillin, and 50 g/ml streptomycin at 37°C in a humidified O 2/CO2 (19:1) atmosphere.
3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cell viability was assessed by examining cell number with the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After treatments, cells were washed twice with PBS; then cell culture medium was removed, and serum-free medium containing 1 mg/ml MTT was added to the cells. After a 2-h incubation, 100 l lysis buffer containing 20% SDS and 50% N,N-dimethyformamide were added and incubated at 37°C overnight. The optical density values were read at 570 nm.
HPLC assay for intracellular AdoMet. The intracellular concentrations of AdoMet and S-adenosylhomocysteine (SAH) were assayed by reverse-phase HPLC with deprotenized extracts of cells by a modified method of Merali et al. (25) . Cell pellets were mixed with 0.25 ml of 4% metaphosphoric acid (MPA) and centrifuged at 10,000 g for 2 min. The supernatants were collected for HPLC analysis. The HPLC system was equipped with a Waters 501 pump, a manual injector, and a 5-m Hypersil C18 reverse-phase column (250 ϫ 4.6 mm). The mobile phase consisted of 40 mM ammonium phosphate, 8 mM heptane sulfonic acid (ionpairing reagent), and 6% acetonitrile (pH 5.0) and it was run isocratically at a constant rate of 1.0 ml/min. AdoMet and SAH were detected using a Waters 740 detector at 254 nm. Standard solutions of AdoMet and SAH were prepared in 4% MPA. An internal standard, S-adenosylethionine (SAE), was added to all samples and standard solutions to a concentration of 100 nmol/ml. Protein concentrations were measured by a protein assay kit from BioRad in accordance with the manufacturer's instructions.
ELISA assay for IL-10, TNF-␣, and cAMP. IL-10 and TNF-␣ in conditioned medium and cAMP were quantified using ELISA kits in accordance with the manufacturer's instructions. The detection limitation for IL-10 and TNF-␣ is 4.0 and 13.5 pg/ml, respectively, and the limit for cAMP is 0.39 pmol/ml. Whereas samples for IL-10 assay were run undiluted, samples for TNF-␣ and cAMP were fivefold diluted. All assays were run in triplicate.
RPA of IL-10 mRNA. Total RNA was isolated with TRIzol reagent (GIBCO-BRL) in accordance with the manufacturer's instructions. IL-10 mRNA was assayed by RPA using RiboQuant multiprobe RNase protection system according to the manufacturer's manual. Briefly, [ 32 P]UTP-labeled RNA probe was prepared by in vitro transcription using multiprobe template set using mCK-2 as a template. Five to ten picograms of total RNA samples were hybridized overnight with purified RNA probe, after which free probe and other single-stranded RNA were digested with RNase A and T1 mix. The remaining RNase-protected probes were purified, resolved on 5% denaturating polyacrylamide gels, and quantitated by autoradiography.
Statistical analyses. All data are expressed as means Ϯ SD. Statistical analysis was performed using one-way ANOVA and further analyzed by Newman-Keuls test for statistical difference. Differences between treatments were considered to be statistically significant at P Ͻ 0.05. Effects of AdoMet treatment on the release of IL-10 by LPS stimulated RAW cell. The effect of exogenous AdoMet on IL-10 production by macrophages was determined by pretreating RAW cells with AdoMet for 2 h and then stimulating with LPS. After a number of preliminary studies in which the pretreatment period with AdoMet was varied from a few minutes to overnight, we designed this protocol to optimize the changes in LPS-stimulated IL-10 release by RAW cells without affecting their viability. Figure 2 summarizes the dose response of AdoMet-enhanced IL-10 release into the conditioned medium. Cells treated with 100 M AdoMet demonstrated a significant increase in IL-10 production following stimulation by LPS. When the cells were pretreated with 1 mM AdoMet for 2 h, IL-10 production was increased to ϳ200% of that of control cells by 16 h after LPS stimulation. IL-10 production could not be detected in either untreated cells or those treated with 1 mM AdoMet without LPS (data not shown). The viability of these cells, measured by the conversion of MTT to formazan, was unaffected by concentrations of AdoMet up to 1 mM (Ͼ90% viability). Treatment of cells with higher concentrations of AdoMet (e.g., Ն3 mM), however, significantly lowered cellular viability to ϳ70% (data not shown).
RESULTS

Effects of AdoMet treatment on intracellular
Time course changes of LPS-stimulated IL-10 release in the absence or presence of 1 mM AdoMet. In the control cells (no AdoMet), IL-10 levels demonstrated a time-dependent increase during the 24-h culture period (from 34.99 Ϯ 9.9 pg/ml in 2 h to 635.65 Ϯ 48.45 pg/ml in 24 h) after LPS stimulation (Fig. 3) . Compared with control cells, AdoMet-treated cells produced a higher level of IL-10 by 8 h after LPS stimulation. By 24 h after LPS stimulation, IL-10 production by AdoMet-treated cells reached almost twice that in control cells (635.65 Ϯ 48.45 pg/ml in control cells vs. 1,113.53 Ϯ 85.49 pg/ml in AdoMet-treated cells).
Effects of AdoMet and anti-IL-10 antibody on LPSstimulated TNF production. As expected, exogenous AdoMet (2 mM) inhibited TNF production by Ͼ50% (23 Ϯ 0.8 pg/ml in LPS treatment vs. 11.9 Ϯ 1.3 pg/ml in AdoMet ϩ LPS treatment) at 18 h after LPS stimulation. Pretreatment with anti-IL-10 antibody (10 g/ ml) modestly but significantly attenuated the TNF inhibitory effects of AdoMet (15.4 Ϯ 0.6 pg/ml). (Fig. 4) . More than 75% of IL-10 production elicited by LPS was inhibited by ethionine treatment. The viability of RAW cells was not affected by treatment with 3 mM ethionine (viability Ͼ90%). Cycloleucine also induces functional AdoMet deficiency (inhibits nonhepatic MAT activity). Cycloleucine at 20 and 40 mM significantly decreased LPS-stimulated IL-10 production by 24 and 47%, respectively. Adding AdoMet significantly reversed the cycloleucine inhibition (data not shown).
Effect of Ethionine and cycloleucine on IL-10 production by LPS-stimulated RAW cells.
Effects of exogenous AdoMet and ethionine on LPSinduced IL-10 gene expression. RPAs were performed to determine whether the effects of AdoMet and ethionine on IL-10 expression could be attributed to Fig. 4 . Time course of IL-10 release by LPS-stimulated RAW cells in the presence and absence of ethionine. Cells were plated as described in the legend to Fig. 1 , then pretreated with 3 mM ethionine dissolved in medium or an equal volume of medium alone for 2 h. They were then stimulated with 100 ng/ml LPS. Conditioned media were collected at the indicated times and analyzed for IL-10 concentration by ELISA. Values represent means Ϯ SD from 3 separate experiments. *P Ͻ 0.05 compared with control cells. Fig. 2 . Effect of AdoMet on LPS-stimulated IL-10 release. Cells were plated as described in the legend to Fig. 1 . AdoMet was added to the culture medium at various concentrations; after 2-h incubation, LPS was added to the culture medium to a final concentration of 100 ng/ml. Cells were incubated in the continued presence of AdoMet and LPS for a further 16 h. Conditioned media were collected, and IL-10 was quantified by ELISA as described in METHODS. Values represent means Ϯ SD from 3 separate experiments and are expressed as fold of control value (no AdoMet). *P Ͻ 0.05 compared with control cells. changes in IL-10 mRNA levels following exposure to LPS. IL-10 mRNA was detected 4 h after stimulation in both control (LPS alone) and AdoMet-treated cells, but AdoMet-treated cells expressed higher levels of IL-10 mRNA than control cells (Fig. 5) . Whereas it was undetectable at 24 h in control cells, IL-10 mRNA expression in AdoMet-treated cells was prolonged to at least 24 h after stimulation. Ethionine-treated cells expressed lower amounts of IL-10 mRNA than either control or AdoMet-treated cells by 8 h after LPS-stimulation, and IL-10 mRNA returned to undetectable levels in 24 h after stimulation.
Role of cAMP pathway in the elevation of IL-10 production. The effect of exogenous AdoMet on cytosolic cAMP concentrations in macrophages was determined by ELISA, and the results are summarized in Fig. 6 . Cells treated with 1 mM AdoMet showed an increase in intracellular cAMP concentrations from a basal value of 8.84 Ϯ 1.35 to 14.08 Ϯ 0.78 pg/mg protein at 3 h. Intracellular levels of cAMP in AdoMet-treated cells remained significantly elevated for 24 h. To investigate whether the enhancement of IL-10 by AdoMet treatment resulted from increased intracellular cAMP concentration, the inhibitors for adenylyl cyclase and PKA were added to the medium before AdoMet administration, and the results are shown in Fig. 7 . Either 1 mM SQ 22536 (inhibitor of adenylyl cyclase) or 1 M H-89 (inhibitor of PKA) was added to the medium 2 h before AdoMet administration, and LPS was added 2 h later. AdoMet treatment elevated LPS-stimulated IL-10 production significantly. SQ 22536 pretreatment did not change the enhancement of IL-10 by AdoMet administration, whereas H-89 lowered the enhancement slightly.
DISCUSSION
IL-10 is a critical anti-inflammatory cytokine that inhibits the synthesis of proinflammatory cytokines in monocytes, macrophages, lymphocytes, and neutrophils (33) . Exogenous administration of IL-10 has been shown to be hepatoprotective in multiple experimental models of liver injury such as LPS ϩ galactosamine (28), C. parvum ϩ LPS (32), and concanavalin A (Con A) (15) . Exogenous IL-10 has also been used to decrease fibrosis in hepatitis C patients who are nonresponders to interferon therapy (29) and to control the inflammatory response during localized inflammation such as rheumatoid arthritis or systemic inflammation such as sepsis (8) . With the use of IL-10 knockout mice, IL-10 has been shown to inhibit neutrophil infiltration and fibrosis in a carbon tetrachloride model of liver injury (21) . Similarly, IL-10 knockout mice were shown to be more sensitive to acetaminophen hepatoxicity, demonstrating the importance of endogenous anti-inflammatory pathways in attenuating toxin/xenobioticinduced hepatoxicity (3). Lastly, IL-10 knockout mice were shown to be more sensitive to alcohol-induced liver injury in a model of alcohol ϩ LPS hepatoxicity (14) .
Patients with alcoholic cirrhosis have a well-characterized decrease in LPS-stimulated IL-10 production (18, 34) . In vitro studies have suggested that decreased IL-10 production plays a major role in the dysregulated TNF metabolism observed in ALD (18) . Patients with ALD have a significantly higher incidence of an IL-10 polymorphism (13). Mice chronically fed alcohol have decreased LPS-stimulated IL-10 production in conjunction with increased liver injury (14) . Similarly, incubation of a macrophage cell line with alcohol on a chronic basis causes decreased LPS-stimulated IL-10 production (34). Thus there is substantial evidence implicating inadequate IL-10 levels in many types of experimental and clinical liver disease, and there is an emerging rationale for exogenous IL-10 therapy or Fig. 5 . RNase protection assay (RPA) of IL-10 mRNA in the presence and absence of AdoMet. After 2 h of pretreatment with 1 mM AdoMet or medium alone, RAW cells were stimulated with 100 ng/ml LPS in the continued presence of AdoMet. Cells were collected at the indicated times after exposure to LPS, the RNA was isolated for RPA assay as described in METHODS. This is a representative example of 3 separate experiments. therapy with drugs that increase endogenous IL-10 in these liver diseases.
Subnormal hepatic AdoMet levels have been reported in various experimental models of liver injury, and AdoMet therapy in rats attenuates liver injury due to cholestasis, ethanol, carbon tetrachloride, fatty liver, acetaminophen, or galactosamine (7, 20, 35, 36) . Liver-specific MAT knockout mice are highly susceptible to another "stress" such as a choline-deficient diet and develop fatty liver and periportal inflammation (23) . MAT deficiency modulates the expression of many genes, especially those involved in proliferation and growth, and normal MAT activity appears to be important for maintaining the hepatocyte in a "differentiated" state. AdoMet downregulates production of the cytotoxic proinflammatory cytokine TNF-␣ in animal models of liver injury and in peripheral blood monocytes or macrophage cell lines in vitro (6, 38) .
Patients with alcoholic cirrhosis who were randomized to receive AdoMet (1,200 mg/day orally) for 2 yr had decreased mortality/liver transplantation (16 vs. 30%) compared with the placebo-treated group (24) . AdoMet has also been used successfully in various types of cholestatic liver disease (19) . Thus there are animal studies and emerging clinical data indicating that AdoMet may be useful in several forms of liver disease.
In this study, we show that exogenous AdoMet enhanced LPS-induced IL-10 production in cultured RAW cells in a time-and dose-response fashion. Supplementation of RAW cells with AdoMet also increased IL-10 mRNA in response to LPS. Ethionine, which is converted to SAE, induces functional AdoMet deficiency. AdoMet deficiency induced by ethionine administration decreased IL-10 mRNA and protein secretion. Similarly, cycloleucine (which blocks extrahepatic MAT activity) also significantly inhibited LPS-stimulated IL-10 production. Thus, in this cell line widely used to study cytokine metabolism, it appears that AdoMet concentrations critically regulate LPS-stimulated IL-10 production. AdoMet also inhibits TNF production. With the use of anti-IL-10 antibody, we showed that a small, but significant, component of AdoMet's anti-TNF activity may be mediated through enhanced IL-10 production.
Data on whether or not AdoMet can be taken up intact by cells are still controversial (10, 39) . We observed an approximately threefold increase in intracellular AdoMet concentration after supplementation with 1 mM exogenous AdoMet, although we did not examine the mechanisms by which this increase occurred. Such an increase could have resulted from either a change in its endogenous metabolism or from cellular uptake of the exogenous AdoMet.
There are multiple potential mechanisms whereby exogenous AdoMet may increase LPS-stimulated IL-10, with one possibility being increased cAMP. The anti-inflammatory functions of cAMP-elevating agents have been demonstrated in several cell systems including inhibition of TNF synthesis and enhancement of IL-10 synthesis both in human and murine monocytes. Previous studies (1, 5, 26, 31) reported that dibutyryl cAMP, an exogenous cAMP, upregulated IL-10 production both in LPS-stimulated human monocytes and Con A-stimulated CD8 ϩ T cell clones. Drugs that elevate intracellular cAMP (e.g., iloprost, pentoxifylline, prostaglandin E 2 ) augmented LPS-induced IL-10 production both at the protein and mRNA levels in human monocytes (11, 16) . We demonstrated for the first time that supplementation of exogenous AdoMet to RAW cells increased intracellular cAMP concentrations as early as 3 h after AdoMet treatment. To investigate whether enhancement of IL-10 production in RAW cells treated with AdoMet involved the cAMP pathway, inhibitors for both adenylyl cyclase and PKA were used. Inhibition of adenylyl cyclase had no effect on IL-10 production, whereas the inhibition of PKA lowered IL-10 production only slightly. Thus, although the cAMP levels increased, it seems unlikely that the cAMP pathway plays a major role in the enhancement of LPS-induced IL-10 production in RAW cells treated with AdoMet.
In conclusion, this research demonstrates that AdoMet concentrations critically regulate LPS-stimulated IL-10 production in monocytes and that AdoMet elevated protein synthesis and gene expression of IL-10 in LPS-stimulated RAW cells. Although the focus of our research and this discussion has been on liver disease, the implications of this work extend far beyond hepatic diseases to other processes ranging from sepsis to rheumatoid arthritis, where modulation of IL-10 appears to play an important role in disease activity/progression. 
